Your browser doesn't support javascript.
loading
CMV retinitis in patients on mycophenolate immunosuppression: a report of two cases.
Patel, Prem N; Alkaliby, Ahmed M; Mehta, Mitul C; Wang, Angeline L.
Afiliación
  • Patel PN; Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9057, USA. prem.patel@utsouthwestern.edu.
  • Alkaliby AM; Gavin Herbert Eye Institute, UC Irvine, Irvine, CA, 92697, USA.
  • Mehta MC; Gavin Herbert Eye Institute, UC Irvine, Irvine, CA, 92697, USA.
  • Wang AL; Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9057, USA.
Allergy Asthma Clin Immunol ; 19(1): 72, 2023 Aug 19.
Article en En | MEDLINE | ID: mdl-37598216
ABSTRACT

BACKGROUND:

The rate of cytomegalovirus (CMV) retinitis is increasing, likely secondary to aggressive immunosuppressive regimens for a variety of diseases. Transplant and rheumatological literature show growing evidence suggesting a unique relationship between CMV infection and mycophenolate in particular. This study reports two cases of CMV retinitis infection in patients on mycophenolate immunosuppression. CASE PRESENTATION Case A was a 39-year-old African American woman with systemic lupus erythematosus (SLE) with stage IV lupus nephritis who presented for bilateral retinal detachments with areas of moth-eaten and thin retina concerning for prior viral retinitis. Case B was a 53-year-old man who presented with floaters in the right eye status-post heart transplant since 2008 on immunosuppressive therapy. Fundoscopic examination of the right eye showed frosted branch angiitis with intraretinal hemorrhage and inner retinal thickening and disorganization, consistent with CMV retinitis infection. Both patients were on mycophenolate immunosuppression with the recommendation to reduce or discontinue mycophenolate.

CONCLUSION:

Patients on mycophenolate immunosuppression may be more vulnerable to cytomegalovirus infection, including CMV retinitis. Ophthalmologists should be aware of this increased risk and consider reducing or discontinuing mycophenolate to promote viral clearance in these susceptible patients, in conjunction with the patient's transplant or rheumatology teams.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Allergy Asthma Clin Immunol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Allergy Asthma Clin Immunol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos